{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:39:58Z","timestamp":1770914398999,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.ajo.2011.11.008","type":"journal-article","created":{"date-parts":[[2012,2,4]],"date-time":"2012-02-04T06:33:01Z","timestamp":1328337181000},"page":"1187-1196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Randomized Clinical Trial of the Efficacy and Safety of Preservative-free Tafluprost and Timolol in Patients With Open-Angle Glaucoma or Ocular Hypertension"],"prefix":"10.1016","volume":"153","author":[{"given":"Almira","family":"Chabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Varma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lupinacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Pigeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Baranak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliane","family":"Noble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Lines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony W.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ajo.2011.11.008_bib1","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1517\/14656560903300129","article-title":"Pharmacotherapy of intraocular pressure - part II","volume":"10","author":"Costagliola","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2011.11.008_bib2","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.survophthal.2008.08.010","article-title":"Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction","volume":"53","author":"Toris","year":"2008","journal-title":"Surv Ophthalmol"},{"issue":"16","key":"10.1016\/j.ajo.2011.11.008_bib3","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1517\/14656560903300103","article-title":"Pharmacotherapy of intraocular pressure: part I","volume":"10","author":"Costagliola","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.ajo.2011.11.008_bib4","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.ophtha.2010.03.024","article-title":"The intraocular pressure-lowering effect of prostaglandin analogs combined with topical \u03b2-blocker therapy: a systematic review and meta-analysis","volume":"117","author":"Webers","year":"2010","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2011.11.008_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000225963","article-title":"Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost","volume":"42","author":"Cheng","year":"2009","journal-title":"Ophthalmic Res"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2011.11.008_bib6","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.survophthal.2008.08.011","article-title":"A review of additivity to prostaglandin analogs: fixed and unfixed combinations","volume":"53","author":"Tabet","year":"2008","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2011.11.008_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00002512-199609050-00007","article-title":"Latanoprost","volume":"9","author":"Patel","year":"1996","journal-title":"Drugs Aging"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2011.11.008_bib8","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","article-title":"Side effects associated with prostaglandin analog therapy","volume":"53","author":"Alm","year":"2008","journal-title":"Surv Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2011.11.008_bib9","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S0039-6257(02)00308-9","article-title":"Current status of prostaglandin therapy: latanoprost and unoprostone","volume":"47","author":"Susanna","year":"2002","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"10.1016\/j.ajo.2011.11.008_bib10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2165\/11203210-000000000-00000","article-title":"Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension","volume":"26","author":"Curran","year":"2009","journal-title":"Drugs Aging"},{"issue":"7","key":"10.1016\/j.ajo.2011.11.008_bib11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1517\/14656566.3.7.965","article-title":"Travoprost - a new prostaglandin analogue for the treatment of glaucoma","volume":"3","author":"Whitson","year":"2002","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.ajo.2011.11.008_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0039-6257(80)90072-7","article-title":"Corneal cytotoxicity of topically applied drugs, vehicles and preservatives","volume":"25","author":"Burstein","year":"1980","journal-title":"Surv Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2011.11.008_bib13","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1755-3768.2008.01250.x","article-title":"Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma","volume":"86","author":"Baudouin","year":"2008","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2011.11.008_bib14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication","volume":"86","author":"Pisella","year":"2002","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2011.11.008_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1358\/dot.2010.46.6.1482107","article-title":"A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension","volume":"46","author":"Hommer","year":"2010","journal-title":"Drugs Today (Barc)"},{"issue":"5","key":"10.1016\/j.ajo.2011.11.008_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/ACI.0b013e3283306990","article-title":"Allergy to ophthalmic preservatives","volume":"9","author":"Hong","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.ajo.2011.11.008_bib17","series-title":"TIMOPTIC\u00ae (timolol maleate) preservative free sterile ophthalmic solution","year":"2005"},{"issue":"12","key":"10.1016\/j.ajo.2011.11.008_bib18","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00417-010-1397-7","article-title":"Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide\/timolol fixed combination(COSOPT\u00a9)in patients with elevated intraocular pressure in a randomized clinical trial","volume":"248","author":"Shedden","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2011.11.008_bib19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exer.2003.12.007","article-title":"Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug","volume":"78","author":"Takagi","year":"2004","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ajo.2011.11.008_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/OPTH.S6368","article-title":"Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension","volume":"4","author":"Aihara","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2011.11.008_bib21","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2147\/OPTH.S6369","article-title":"Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension","volume":"4","author":"Pozarowska","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2011.11.008_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1755-3768.2010.01907.x","article-title":"Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication","volume":"88","author":"Uusitalo","year":"2010","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2011.11.008_bib23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/112067210901900207","article-title":"Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma","volume":"19","author":"Egorov","year":"2009","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2011.11.008_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/jop.2009.0066","article-title":"A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost","volume":"26","author":"Traverso","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ajo.2011.11.008_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1755-3768.2010.01862.x","article-title":"Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study","volume":"88","author":"Uusitalo","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ajo.2011.11.008_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1755-3768.2008.01381.x","article-title":"Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis","volume":"242","author":"Hamacher","year":"2008","journal-title":"Acta Ophthalmol Suppl (Oxf)"},{"issue":"9","key":"10.1016\/j.ajo.2011.11.008_bib27","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/sj.eye.6701345","article-title":"Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma","volume":"18","author":"Konstas","year":"2004","journal-title":"Eye (Lond)"},{"issue":"1","key":"10.1016\/j.ajo.2011.11.008_bib28","first-page":"23","article-title":"Timolol maleate a gold standard drug in glaucoma used as ocular film ans inserts: an overview","volume":"3","author":"Rathore","year":"2010","journal-title":"International Journal of Pharmaceutical Sciences Review and Research"},{"issue":"7","key":"10.1016\/j.ajo.2011.11.008_bib29","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials","volume":"112","author":"Van der Valk","year":"2005","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2011.11.008_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"issue":"8","key":"10.1016\/j.ajo.2011.11.008_bib31","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archopht.1996.01100140137004","article-title":"A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension","volume":"114","author":"Mishima","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2011.11.008_bib32","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","article-title":"A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study","volume":"135","author":"Parrish","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2011.11.008_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archophthalmol.2009.384","article-title":"Fixed combination of latanoprost andtimolol vs. individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study","volume":"128","author":"Higginbotham","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2011.11.008_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1755-3768.2008.01380.x","article-title":"Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers","volume":"242","author":"Uusitalo","year":"2008","journal-title":"Acta Ophthalmol Suppl (Oxf)"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939411008658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939411008658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:05:49Z","timestamp":1757595949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939411008658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0002939411008658"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2011.11.008","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Clinical Trial of the Efficacy and Safety of Preservative-free Tafluprost and Timolol in Patients With Open-Angle Glaucoma or Ocular Hypertension","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2011.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}